MCID: ABD014
MIFTS: 48

Abdominal Obesity-Metabolic Syndrome 1

Categories: Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome 1

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome 1:

Name: Abdominal Obesity-Metabolic Syndrome 1 54 12
Metabolic Syndrome X 12 29 52 42 14 69
Abdominal Obesity Metabolic Syndrome 69
Dysmetabolic Syndrome X 12

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant


Classifications:



External Ids:

OMIM 54 605552
Disease Ontology 12 DOID:14221
ICD10 33 E88.81
ICD9CM 35 277.7
MeSH 42 D024821
NCIt 47 C84442
SNOMED-CT 64 190394009 237602007
UMLS 69 C0524620

Summaries for Abdominal Obesity-Metabolic Syndrome 1

OMIM : 54
A clustering of abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol (HDLC), high blood pressure, and elevated fasting glucose levels is sometimes called metabolic syndrome X (Reaven, 1988) or abdominal obesity-metabolic syndrome (Bjorntorp, 1991). The syndrome may affect nearly 1 in 4 U.S. adults and is considered a veritable epidemic (Ford et al., 2002). It is a major risk factor for both diabetes mellitus (see 125853 and Haffner et al., 1992) and cardiovascular disease (Isomaa et al., 2001). The etiology is complex, determined by the interplay of both genetic and environmental factors. The prevalence varies substantially among ethnic groups, with the highest rates in Mexican American women (Park et al., 2003). Other factors influencing the metabolic syndrome include age, smoking, alcohol, diet, and physical inactivity. (605552)

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome 1, also known as metabolic syndrome x, is related to abdominal obesity-metabolic syndrome and lipodystrophy, familial partial, type 2, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Abdominal Obesity-Metabolic Syndrome 1 is MTTP (Microsomal Triglyceride Transfer Protein), and among its related pathways/superpathways are Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Eplerenone and Spironolactone have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and heart, and related phenotypes are adipose tissue and growth/size/body region

Related Diseases for Abdominal Obesity-Metabolic Syndrome 1

Diseases in the Abdominal Obesity-Metabolic Syndrome family:

Abdominal Obesity-Metabolic Syndrome 1 Abdominal Obesity-Metabolic Syndrome 3

Diseases related to Abdominal Obesity-Metabolic Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Related Disease Score Top Affiliating Genes
1 abdominal obesity-metabolic syndrome 10.8
2 lipodystrophy, familial partial, type 2 10.4 INS LEP
3 acute myocarditis 10.3 HSD11B1 INS
4 fetal parvovirus syndrome 10.3 INS LEP
5 alstrom syndrome 10.2 INS LEP
6 cervix squamous papilloma 10.1 HSD11B1 SERPINE1
7 acquired hypoprothrombinemia 10.1 ADIPOQ LEP
8 leigh syndrome with leukodystrophy 10.1 ADIPOQ LEP
9 chondroma 10.1 INS LEP
10 scleredema adultorum 10.0 ADIPOQ LEP
11 not otherwise specified 3-mga-uria type 10.0 ADIPOQ LEP
12 precursor b lymphoblastic lymphoma/leukemia 10.0 HSD11B1 INS LEP
13 corpus callosum agenesis of blepharophimosis robin type 10.0 ADIPOQ LEP
14 exostosis 10.0 INS LEP SERPINE1
15 porokeratosis 10.0 INS LEP
16 obesity 9.9
17 hyperchylomicronemia, late-onset 9.8 ADIPOQ INS SERPINE1
18 mucinoses 9.8 ADIPOQ INS LEP
19 diabetic encephalopathy 9.8 ADIPOQ INS LEP
20 periampullary adenoma 9.8 ADIPOQ INS LEP
21 exophthalmic ophthalmoplegia 9.8 ADIPOQ LEP
22 achard thiers syndrome 9.8 ADIPOQ PPARG
23 peripheral artery disease 9.8 ADIPOQ INS SERPINE1
24 dientamoebiasis 9.8 ADIPOQ INS LEP
25 hidradenoma 9.7 LEP SERPINE1
26 cataract, autosomal dominant congenital 4 9.7 INS PPARG SERPINE1
27 atherosclerosis 9.7
28 lymphoblastic lymphoma 9.7 ADIPOQ INS LEP
29 macular degeneration, age-related, 12 9.6 ADIPOQ INS SERPINE1
30 lissencephaly 9.6 INS LEP PPARG
31 myocardial infarction 9.5
32 acute myocardial infarction 9.5
33 heart disease 9.5
34 cushing's syndrome 9.5
35 central retinal artery occlusion 9.5
36 vascular disease 9.5
37 retinitis 9.5
38 hyperglycemia 9.5
39 retinal artery occlusion 9.5
40 idiopathic juxtafoveal retinal telangiectasia 9.5 ADIPOQ INS PPARG
41 hyperinsulinemic hypoglycemia, familial, 4 9.4 ADIPOQ INS PPARG
42 myh-9 related disease 9.4 DBI INS LEP SLC2A4
43 hypertension, essential 9.4 ADIPOQ INS LEP SERPINE1
44 neurogenic arthropathy 9.3 ADIPOQ INS LEP SLC2A4
45 short bowel syndrome 9.3 ADIPOQ INS LEP SLC2A4
46 antidepressant type abuse 9.3 ADIPOQ INS LEP SLC2A4
47 myelophthisic anemia 9.0 ADIPOQ INS PPARG SERPINE1
48 hyperlipoproteinemia type iv 9.0 ADIPOQ INS LEP PPARG
49 pericarditis 9.0 ADIPOQ INS PPARG SERPINE1
50 mucolipidoses 9.0 ADIPOQ INS LEP PPARG

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome 1:



Diseases related to Abdominal Obesity-Metabolic Syndrome 1

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome 1

Symptoms via clinical synopsis from OMIM:

54

Laboratory- Abnormalities:
elevated fasting glucose levels

Growth- Weight:
abdominal obesity

Cardiovascular- Vascular:
hypertension


Clinical features from OMIM:

605552

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome 1:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.11 ADIPOQ DBI HSD11B1 INS LEP PPARG
2 growth/size/body region MP:0005378 10.11 SERPINE1 SLC2A4 ADIPOQ DBI HSD11B1 INS
3 cardiovascular system MP:0005385 10.1 ADIPOQ HSD11B1 INS LEP MTTP PPARG
4 homeostasis/metabolism MP:0005376 10.06 ADIPOQ DBI HSD11B1 INS LEP MTTP
5 hematopoietic system MP:0005397 9.98 ADIPOQ HSD11B1 INS LEP MTTP PPARG
6 endocrine/exocrine gland MP:0005379 9.95 ADIPOQ HSD11B1 INS LEP PPARG SLC2A4
7 immune system MP:0005387 9.91 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
8 liver/biliary system MP:0005370 9.91 LEP MTTP PPARG SERPINE1 SLC2A4 ADIPOQ
9 integument MP:0010771 9.87 ADIPOQ DBI HSD11B1 INS LEP PPARG
10 mortality/aging MP:0010768 9.76 INS LEP MTTP PPARG SERPINE1 SLC2A4
11 muscle MP:0005369 9.43 ADIPOQ HSD11B1 INS LEP PPARG SLC2A4
12 renal/urinary system MP:0005367 9.02 ADIPOQ INS LEP PPARG SERPINE1

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome 1

Drugs for Abdominal Obesity-Metabolic Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 390)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eplerenone Approved Phase 4 107724-20-9 150310 443872
2
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
3
Valsartan Approved, Investigational Phase 4,Phase 1 137862-53-4 60846
4
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
5
Amlodipine Approved Phase 4,Phase 2,Phase 1 88150-42-9 2162
6
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 58-93-5 3639
7
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
8
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
9
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
10
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
11
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 1 122320-73-4 77999
12
Clozapine Approved Phase 4 5786-21-0 2818
13
Galantamine Approved Phase 4 357-70-0 9651
14
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
15
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
16
Ziprasidone Approved Phase 4,Phase 3 146939-27-7 60854
17
Infliximab Approved Phase 4 170277-31-3
18
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 111025-46-8 4829
19
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
20
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
21
Nitric Oxide Approved Phase 4 10102-43-9 145068
22
Losartan Approved Phase 4,Phase 3 114798-26-4 3961
23
Trandolapril Approved Phase 4 87679-37-6 5484727
24
Verapamil Approved Phase 4 52-53-9 2520
25
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
26
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
27
Atenolol Approved Phase 4 29122-68-7 2249
28
Bisoprolol Approved Phase 4 66722-44-9 2405
29 Titanium dioxide Approved Phase 4 13463-67-7
30
Fenofibrate Approved Phase 4,Phase 2 49562-28-9 3339
31
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
32
Fluvastatin Approved Phase 4 93957-54-1 1548972
33
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
34
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
35
Telmisartan Approved, Investigational Phase 4,Phase 3 144701-48-4 65999
36
Moxonidine Approved Phase 4 75438-57-2 4810
37
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
38
Enalaprilat Approved Phase 4 76420-72-9 6917719
39
Pitavastatin Approved Phase 4,Phase 1 147511-69-1, 147526-32-7 6366718 5282452
40
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
41
Ramipril Approved Phase 4,Phase 1,Early Phase 1 87333-19-5 5362129
42
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
43
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
44
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
45
Norgestimate Approved Phase 4 35189-28-7 6540478
46
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 1,Phase 2 67-97-0 6221 10883523 5280795
47
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-14-6 5280793
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 1406-16-2
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
50
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2 59-67-6 938

Interventional clinical trials:

(show top 50) (show all 453)

id Name Status NCT ID Phase Drugs
1 Diurnal Variation of Plasminogen Activator Inhibitor-1 Unknown status NCT00515021 Phase 4 Eplerenone (Morning vs. evening drug regimen)
2 Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study) Unknown status NCT00790946 Phase 4 Valsartan
3 The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome Unknown status NCT01357382 Phase 4
4 Metformin in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
5 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
6 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
7 Effect of Growth Hormone in Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
8 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
9 Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage Unknown status NCT00517777 Phase 4
10 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
11 Galantamine Effects in Patients With Metabolic Syndrome Completed NCT02283242 Phase 4 Galantamine;Placebo (for galantamine)
12 ROMEO (Rosuvastatin in Metabolic syndrOme) Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
13 Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes Completed NCT00338949 Phase 4 Ziprasidone;Standard atypical antipsychotic drug
14 Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity Completed NCT00636142 Phase 4
15 Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults Completed NCT00352287 Phase 4 Recombinant human growth hormone; pioglitazone
16 Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093) Completed NCT00157924 Phase 4 simvastatin (+) ezetimibe;atorvastatin
17 The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study) Completed NCT00346970 Phase 4 Extended-Release Niacin;Placebo
18 Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR) Completed NCT00234858 Phase 4 trandolapril/verapamil;(Hyzaar) losartan/hydrochlorothiazide
19 Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment Completed NCT00819403 Phase 4 simvastatin;ezetimibe/simvastatin
20 Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome Completed NCT00110422 Phase 4 Irbesartan;Hydrochlorothiazide
21 Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome Completed NCT00272311 Phase 4 Aspirin
22 Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism Completed NCT00287820 Phase 4 Olanzapine;olanzapine;risperidone
23 Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol Completed NCT01939509 Phase 4 Atenolol;Bisoprolol
24 Mesoglycan, Vascular Reactivity and Metabolic Syndrome Completed NCT02254850 Phase 4 Mesoglycan;Mesoglycan;Placebo;Placebo
25 Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia Completed NCT00304993 Phase 4 fenofibrate;niacin;rosiglitazone
26 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
27 Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle. Completed NCT02129725 Phase 4 Sildenafil citrate;Placebo Oral Capsule
28 Effect of Testosterone Replacement on Insulin Resistance Completed NCT00487734 Phase 4 Placebo for testosterone gel
29 Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome Completed NCT00821574 Phase 4 Fluvastatin;Valsartan;Hydrochlorothiazide
30 Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Completed NCT00416741 Phase 4
31 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
32 Regulation of Lipoprotein Transport in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
33 Magnesium and Metabolic Syndrome Completed NCT00603499 Phase 4
34 Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome Completed NCT01714011 Phase 4 Ziprasidone;Aripiprazole
35 Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes Completed NCT00306644 Phase 4 Rosiglitazone
36 The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome Completed NCT00926341 Phase 4 Pioglitazone;Telmisartan
37 Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities Completed NCT00242814 Phase 4 Micardis;Amlodipine
38 Mechanisms Underlying Metabolic Syndrome in Obesity Completed NCT00579813 Phase 4 Pioglitazone
39 Treatment of Adiposity Related hypErTension (TARGET) Completed NCT01138423 Phase 4 Aliskiren;Moxonidine;Hydrochlorothiazide;Placebo (for aliskiren);Placebo (for moxonidine and hydrochlorothiazide)
40 Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome Completed NCT00666848 Phase 4 Placebo;Enalapril 5mg;Enalapril 10mg;Sitagliptin
41 Impact of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome Completed NCT00444717 Phase 4 pitavastatin
42 Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease Completed NCT03011775 Phase 4 Pioglitazone 15 mg Tablet;Isosorbide Dinitrate 10Mg Tablet;Acetylsalicylic Acid 75Mg Tablet;Bisoprolol Fumarate 2.5 MG Oral Tablet;Rosuvastatin Calcium 20 MG Oral Tablet;ramipril 5 MG
43 Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities Completed NCT02751307 Phase 4 metformin 500 mg;clozapine 100 mg
44 Niacin, N-3 Fatty Acids and Insulin Resistance Completed NCT00286234 Phase 4 omega-3 acid ethyl esters;extended release niacin;placebo;omega-3 acid ethyl esters;combined treatment
45 Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome Completed NCT00738400 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
46 Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome Completed NCT00815659 Phase 4 rosuvastatin
47 Aldosterone Antagonism and Microvascular Function Recruiting NCT01887119 Phase 4 Eplerenone
48 Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome Recruiting NCT02940366 Phase 4 Pitavastatin 4 mg orally daily;Atorvastatin 20 mg orally daily
49 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent Recruiting NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
50 A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome Recruiting NCT02968160 Phase 4 Telmisartan 40mg + Rosuvastatin 20mg;Telmisartan 80mg + Rosuvastatin 20mg;Telmisartan 40mg, 80 mg;Rosuvastatin 20mg

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome 1

Cochrane evidence based reviews: metabolic syndrome x

Genetic Tests for Abdominal Obesity-Metabolic Syndrome 1

Genetic tests related to Abdominal Obesity-Metabolic Syndrome 1:

id Genetic test Affiliating Genes
1 Metabolic Syndrome X 29

Anatomical Context for Abdominal Obesity-Metabolic Syndrome 1

MalaCards organs/tissues related to Abdominal Obesity-Metabolic Syndrome 1:

39
Liver, Endothelial, Heart, Bone, Brain, Breast, Prostate

Publications for Abdominal Obesity-Metabolic Syndrome 1

Variations for Abdominal Obesity-Metabolic Syndrome 1

Expression for Abdominal Obesity-Metabolic Syndrome 1

Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome 1.

Pathways for Abdominal Obesity-Metabolic Syndrome 1

Pathways related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 ADIPOQ DBI LEP PPARG SLC2A4
2
Show member pathways
12.54 ADIPOQ INS LEP SLC2A4
3 12.26 ADIPOQ INS PPARG SLC2A4
4
Show member pathways
12.14 ADIPOQ INS LEP PPARG SLC2A4
5
Show member pathways
11.97 INS LEP SLC2A4
7
Show member pathways
11.89 ADIPOQ INS PPARG
8
Show member pathways
11.67 ADIPOQ INS SLC2A4
9 11.54 ADIPOQ INS LEP PPARG SLC2A4
10 11.52 DBI INS PPARG
11 11.49 ADIPOQ DBI PPARG
12 11.45 ADIPOQ LEP SLC2A4
13 11.31 LEP SLC2A4
14 11.28 INS LEP
15 11.22 INS SLC2A4
16 11.22 ADIPOQ INS LEP PPARG SERPINE1 SLC2A4
17 11.03 INS SLC2A4
18 10.94 ADIPOQ LEP PPARG
19 10.73 INS SLC2A4
20 10.6 ADIPOQ LEP PPARG SLC2A4

GO Terms for Abdominal Obesity-Metabolic Syndrome 1

Cellular components related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 8.8 DBI INS MTTP

Biological processes related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.86 HSD11B1 LEP MTTP PPARG
2 response to ethanol GO:0045471 9.63 ADIPOQ LEP SLC2A4
3 fatty acid beta-oxidation GO:0006635 9.62 ADIPOQ LEP
4 response to activity GO:0014823 9.61 ADIPOQ LEP
5 placenta development GO:0001890 9.61 LEP PPARG
6 negative regulation of smooth muscle cell proliferation GO:0048662 9.6 ADIPOQ PPARG
7 brown fat cell differentiation GO:0050873 9.59 ADIPOQ SLC2A4
8 positive regulation of glucose import GO:0046326 9.58 ADIPOQ INS
9 glucose transport GO:0015758 9.58 INS SLC2A4
10 positive regulation of interleukin-8 production GO:0032757 9.57 ADIPOQ SERPINE1
11 lipoprotein transport GO:0042953 9.55 MTTP PPARG
12 positive regulation of cellular protein metabolic process GO:0032270 9.54 ADIPOQ INS
13 regulation of fat cell differentiation GO:0045598 9.52 LEP PPARG
14 fatty acid oxidation GO:0019395 9.51 ADIPOQ PPARG
15 response to nutrient GO:0007584 9.5 ADIPOQ LEP PPARG
16 negative regulation of gluconeogenesis GO:0045721 9.49 ADIPOQ INS
17 negative regulation of smooth muscle cell migration GO:0014912 9.48 ADIPOQ SERPINE1
18 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.43 ADIPOQ PPARG
19 cellular response to insulin stimulus GO:0032869 9.43 ADIPOQ PPARG SLC2A4
20 positive regulation of insulin receptor signaling pathway GO:0046628 9.4 INS LEP
21 negative regulation of acute inflammatory response GO:0002674 9.37 INS PPARG
22 glucose metabolic process GO:0006006 9.33 ADIPOQ INS LEP
23 circadian rhythm GO:0007623 9.26 ADIPOQ LEP MTTP SERPINE1
24 glucose homeostasis GO:0042593 9.02 ADIPOQ INS LEP PPARG SLC2A4

Molecular functions related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 ADIPOQ INS LEP

Sources for Abdominal Obesity-Metabolic Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....